<DOC>
	<DOCNO>NCT02022007</DOCNO>
	<brief_summary>The objective present proposal compare clinical , endocrine metabolic effect therapy combination saxagliptin metformin saxagliptin metformin monotherapy woman PCOS prediabetic hyperglycemia ( IFG , IGT IFG/IGT ) . Saxagliptin oral dipeptidyl peptidase IV ( DPP-4 ) inhibitor whose mechanism action prolong duration blood glucagon-like peptide ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) level inhibit degradation thereby augment insulin secretion . This study serve pilot investigation open perspectives future study explore potential combine anti-diabetic drug different mechanism action patient PCOS impair glucose regulation ( IGR ) , especially one standard treatment metformin less effective .</brief_summary>
	<brief_title>Saxagliptin + Metformin Compared Saxagliptin Metformin Monotherapy PCOS Women With Impaired Glucose Homeostasis</brief_title>
	<detailed_description>A major change treatment polycystic ovary syndrome ( PCOS ) initiate understand many woman disorder compensate insulin resistance period hypersecretion insulin pancreatic ß-cell . In addition , woman PCOS significantly high basal insulin secretory rate , reduce insulin clearance rate , attenuate secretory response meal . The decreased postprandial response patient resemble ß-cell dysfunction type 2 diabetes ( DM2 ) may account increase incidence impair glucose tolerance population . Current research show use diabetes management practice aim reduce insulin resistance hyperinsulinemia ( weight reduction administration oral antidiabetic drug ) woman PCOS improve glucose lipid metabolism also reverse testosterone abnormality restore menstrual cycle . The optimal modality long-term treatment PCOS positively influence androgen synthesis , sex hormone bind globulin ( SHBG ) production , lipid profile , insulin sensitivity , clinical symptom include hirsutism irregular menstrual cycle . Improvement insulin sensitivity may reverse demand ß-cell promote improvement glucose tolerance . However , insulin resistance play key role predisposition diabetes PCOS ; defect insulin secretion also appear contribute development . Preferably therapy woman PCOS also produce weight gain , hypoglycemia , limit unmanageable side effect well preserve enhance ß-cell function . Presently , literature , describe new , efficient method diabetes prevention group high risk disorder , involve , lifestyle modification pharmacological therapy . Lifestyle intervention find reduce incidence type 2 diabetes 58 % metformin 31 % compare placebo . The use rosiglitazone subject prediabetes result 60 % reduction diabetes incidence rate . Whether pharmacological therapy prescribe diabetes prevention open question give wait add drug therapy diabetes develops arrest β-cell decline , albeit low level β-cell function medication use prevention . Studies need optimal postpartum long-term health woman GDM . Considerable recent evidence suggest incretin-based therapy may useful prevention DM2 . Whereas native GLP-1 short half-life , continuous infusion GLP-1 improve first second-phase insulin secretion suggest early GLP-1 therapy may preserve ß-cell function subject IGT mild DM2 . Incretin mimetics inhibitor protease dipeptidyl peptidase ( DPP ) -4 use anti-diabetic property incretin hormone , glucagon-like peptide ( GLP ) -1 hormone augment glucose-induced insulin secretion highly glucose-dependent manner , thus prevent GLP-1 alone provoke hypoglycemia . Additional beneficial effect GLP-1 endocrine pancreatic islet 1 ) support synthesis proinsulin replenish insulin store β-cells ; 2 ) reduces rate β-cell apoptosis islet incubate toxic environment ( glucotoxicity , lipotoxicity , cytotoxic cytokine ) ; 3 ) promote differentiation precursor cell ability develop β-cells proliferation β-cell line , whole animal ( rodent study ) , lead increase β-cell mass within day week . Furthermore , GLP-1 low glucagon concentration , i.e. , induce α-cells respond inhibitory action hyperglycemia , leave counterregulatory glucagon response undisturbed , case hypoglycemia . Additional activity GLP-1 deceleration gastric emptying , slow entry nutrient circulation meal , reduction appetite , early induction satiety , lead weight reduction chronic exposure . Inhibition DPP-4 increase concentration GLP-1 may potentially delay disease progression prediabetes consider β-cell function improvement DM2 β-cell mass show increase animal model . The objective present proposal compare clinical , endocrine metabolic effect therapy combination saxagliptin metformin saxagliptin metformin monotherapy woman PCOS prediabetic hyperglycemia ( IFG , IGT IFG/IGT ) . Since aberrant first-phase insulin secretion impair suppression endogenous glucose production major contributor postprandial hyperglycemia development DM2 , effect saxagliptin target defect , normalize glucose excursion likely clinically significant patient PCOS impair glucose regulation . This study evaluate impact treatment combination metformin saxagliptin ( Kombiglyze XR ) compare saxagliptin ( Onglyza ) metformin XR ( Glucophage XR ) monotherapy 16-week period glycemia insulin action ( fasting , 2 hour , mean stimulate glucose level , insulin sensitivity secretion ) , hyperandrogenism ( total T , DHEAS , SHBG calculate free androgen index [ FAI ] ) , cardiometabolic marker ( lipid profile , blood pressure ) , anthropometric measurement ( BMI , waist : hip ratio , absolute weight ) patient PCOS prediabetic hyperglycemia</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Females 18 year 42 year age PCOS ( NIH criterion ) prediabetic hyperglycemia determine 75 gram oral glucose tolerance test ( OGTT ) . Study subject inclusive PCOS woman impair fast glucose ( IFG ) , impair glucose tolerance ( IGT ) , ( IFG/IGT ) . Written consent participation study Presence significant systemic disease , heart problem include congestive heart failure , history pancreatitis , diabetes mellitus ( Type 1 2 ) Any hepatic disease past ( viral hepatitis , toxic hepatic damage , jaundice unknown etiology ) , gallstone , abnormal liver function test renal impairment ( elevate serum creatinine level abnormal creatinine clearance ) Uncontrolled thyroid disease ( document normal TSH ) , Cushing 's syndrome , congenital adrenal hyperplasia hyperprolactinemia Significantly elevate triglyceride level ( fast triglyceride &gt; 400 mg % ) Untreated poorly control hypertension ( sit blood pressure &gt; 160/95 mm Hg ) Use hormonal medication , drug know affect gastrointestinal motility , lipidlowering ( statin , etc . ) and/or antiobesity drug medication interfere carbohydrate metabolism ( isotretinoin , hormonal contraceptive , GnRH analogues , glucocorticoid , anabolic steroid , C19 progestins ) least 8 week . Use antiandrogens act peripherally reduce hirsutism 5alpha reductase inhibitor ( finasteride , spironolactone , flutamide ) least 4 week Prior history malignant disease require chemotherapy Known hypersensitivity contraindication use insulin sensitizer metformin thiazolidinediones History hypersensitivity reaction saxagliptin DPP4 inhibitor ( e.g . anaphylaxis , angioedema , exfoliative skin condition ) Current use metformin , thiazolidinediones , GLP1 receptor agonist , DPP4 inhibitor , weight loss medication ( prescription OTC ) Patients must stop use insulin sensitizer antidiabetic medicine metformin least 4 week thiazolidinediones , GLP1 agonists DPPIV inhibitor 8 week . Prior use medication treat diabetes except gestational diabetes Use drug know exacerbate glucose tolerance Eating disorder ( anorexia , bulimia ) gastrointestinal disorder Suspected pregnancy ( document negative serum ßhCG test ) , desire pregnancy study treatment interval , breastfeeding , know pregnancy last 2 month Active prior history substance abuse ( smoke tobacco use within past 3 year ) significant intake alcohol history alcoholism Patient willing use adequate barrier contraception study period ( unless sterilize IUD ) . Debilitating psychiatric disorder psychosis neurological condition might confound outcome variable Inability refusal comply protocol Not currently participate participate experimental drug study previous three month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PCOS</keyword>
	<keyword>IGT</keyword>
	<keyword>DPP-4 inhibitor</keyword>
</DOC>